{"nctId":"NCT02062385","briefTitle":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","startDateStruct":{"date":"2014-05-30","type":"ACTUAL"},"conditions":["Rotavirus Gastroenteritis"],"count":4040,"armGroups":[{"label":"V260 with staggered EPI","type":"EXPERIMENTAL","interventionNames":["Biological: V260","Biological: OPV","Biological: DTaP"]},{"label":"Placebo with staggered EPI","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo to V260","Biological: OPV","Biological: DTaP"]},{"label":"V260 with concomitant EPI","type":"EXPERIMENTAL","interventionNames":["Biological: V260","Biological: OPV","Biological: DTaP"]},{"label":"Placebo with concomitant EPI","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo to V260","Biological: OPV","Biological: DTaP"]}],"interventions":[{"name":"V260","otherNames":[]},{"name":"Placebo to V260","otherNames":[]},{"name":"OPV","otherNames":[]},{"name":"DTaP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants at least 6 weeks (42 days) and up to 12 weeks (84 days) of age at the time of the first study vaccination\n* Parent/legal guardian agrees to participate by giving written informed consent and is willing and able to comply with study requirements\n\nExclusion Criteria:\n\n* History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic diarrhea, failure to thrive, or abdominal surgery\n* History of intussusception\n* Impairment of immunological function, including Severe Combined Immunodeficiency (SCID)\n* Acute disease, severe chronic disease, or chronic disease during the acute period\n* Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological disease\n* Hypersensitivity to any component of the rotavirus vaccine, OPV, or DTaP\n* Prior receipt of any rotavirus vaccine\n* Fever, with an axillary temperature \\>=37.5 °C (or equivalent) within 24 hours before study vaccination (study vaccination can be deferred until complete resolution of febrile illness)\n* Clinical evidence of active gastrointestinal illness\n* Received intramuscular, oral, or intravenous corticosteroid treatment since birth (topical, ophthalmic, and inhaled steroids are permitted)\n* Resides in a household with an immunocompromised person\n* Receipt of a blood transfusion or blood products, including immunoglobulins\n* Participation in another interventional study within 14 days before the first study vaccination or during the study\n* Receipt of an investigational or non-registered product other than the study vaccine within 30 days before the first study vaccination or during the study\n* For participants in immunogenicity arms: inability to obtain a blood specimen at randomization visit (note: the visit may be rescheduled so that a baseline specimen may be obtained); history of polio, diphtheria, tetanus, or pertussis disease; previous vaccination against diphtheria, tetanus, pertussis, or poliomyelitis\n* Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study objectives","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Any Severity of Rotavirus Gastroenteritis","description":"The number of participants with rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Elevated Temperature","description":"Elevated temperature (temperature \\>=37.5°C axillary or equivalent) was noted by the guardian and recorded on the Vaccination Report Card during Day 1 to Day 14 after each dose of vaccination. Elevated temperature reported by the guardian was also collected as an adverse event (pyrexia) during Day 15 to Day 30 after each dose of vaccination. The percentage of participants with axillary temperature \\>=37.5 °C or an adverse event of pyrexia was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.84","spread":null},{"groupId":"OG001","value":"22.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Vomiting or Diarrhea","description":"Episodes of vomiting and diarrhea were noted by the guardian and recorded on the Vaccination Record Card during Day 1 to Day 14 after each dose of vaccination. Vomiting and diarrhea reported by the guardian were also collected as an adverse event during Day 15 to Day 30 after any dose of vaccination. The percentage of participants with an episode or an adverse event of vomiting or diarrhea was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":null},{"groupId":"OG001","value":"3.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.15","spread":null},{"groupId":"OG001","value":"20.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Intussusception","description":"Episodes of intussusception were collected from the time of written consent until the end of study. The percentage of participants with an episode of intussusception was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severe Rotavirus Gastroenteritis","description":"The number of participants with severe rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms. Severe RVGE was defined as \\>=11 on the Vesikari Scoring System, a composite of the seven parameters related to symptoms and treatment with an overall range from 0 to 20.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3","description":"The percentage of participants who achieved seroprotection against poliovirus Type 1, 2, or 3 was assessed. Seroprotection was defined as a neutralizing antibody titer \\>=1:8. This outcome was evaluated only in participants receiving concomitant administration of V260 and OPV.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.09","spread":null},{"groupId":"OG001","value":"38.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.93","spread":null},{"groupId":"OG001","value":"100.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.09","spread":null},{"groupId":"OG001","value":"41.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":null},{"groupId":"OG001","value":"100.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.27","spread":null},{"groupId":"OG001","value":"21.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.93","spread":null},{"groupId":"OG001","value":"98.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the sponsor's product, is also an adverse event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null},{"groupId":"OG001","value":"53.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Seropositive to Diphtheria, Pertussis, or Tetanus Antigens","description":"The percentage of participants seropositive to diphtheria, pertussis, or tetanus antigens was assessed. Seropositive was defined as the following: 1) anti-diphtheria antibody titers \\>=0.1 International Units (IU)/mL, 2) anti-tetanus antibody titers \\>=0.1 IU/mL, 3) antipertussis toxin antibody titers \\>=20 Enzyme-linked Immunosorbent Assay (ELISA) Units (EU)/mL, 4) anti-pertussis filamentous hemagglutinin (FHA) antibody titers \\>=20 EU/mL. This outcome was evaluated only in participants receiving concomitant administration of V260 and EPI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.31","spread":null},{"groupId":"OG001","value":"2.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.47","spread":null},{"groupId":"OG001","value":"99.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.92","spread":null},{"groupId":"OG001","value":"43.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":null},{"groupId":"OG001","value":"1.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.19","spread":null},{"groupId":"OG001","value":"94.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.15","spread":null},{"groupId":"OG001","value":"12.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":null},{"groupId":"OG001","value":"100.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":339,"n":2015},"commonTop":["Pyrexia","Diarrhoea","Nasopharyngitis","Cough","Upper respiratory tract infection"]}}}